OMER Soars 81% on FDA Approval of Yartemlea: A Game-Changer for TA-TMA Treatment

Summary
• Omeros (OMER) surges 81.14% to $15.85, marking a historic intraday rally.
• FDA approves Yartemlea as the first and only treatment for TA-TMA, a rare transplant complication.
• Retail sentiment on Stocktwits turns 'extremely bullish,' with high message volumes amplifying momentum.
• The stock trades between $13.92 and $17.65, hitting its 52-week high of $17.65.

Omeros’ stock has erupted on the heels of a landmark FDA approval for Yartemlea, its first-in-class therapy for transplant-associated thrombotic microangiopathy (TA-TMA). The 81% surge reflects a confluence of regulatory validation, robust clinical data, and surging retail enthusiasm. With a planned U.S. launch in January 2026 and European regulatory milestones ahead, OMER’s trajectory now hinges on execution and market adoption.

FDA Approval Catalyzes OMER’s Record Rally
The U.S. Food and Drug Administration’s (FDA) approval of Yartemlea (narsoplimab-wuug) for TA-TMA has ignited OMER’s meteoric rise. This first-and-only therapy for a condition affecting up to 56% of allogeneic transplant recipients represents a paradigm shift in hematopoietic stem cell transplantation. Clinical data from the pivotal trial and Expanded Access Program demonstrated 61% and 68% complete response rates, respectively, alongside a 74% 100-day survival rate in high-risk patients. The approval validates Omeros’ decade-long R&D investment and positions Yartemlea as a critical revenue driver. Retail traders, sensing the inflection point, have amplified the move through aggressive buying and social media buzz, particularly on Stocktwits, where sentiment shifted to 'extremely bullish' amid high-volume chatter.

Biotech Sector Rally: AMGN’s Modest Gains vs. OMER’s Volatility
While OMER’s 81% surge dwarfs sector norms, the broader biotechnology index has seen mixed performance. Amgen (AMGN), the sector’s leader, rose 0.4% intraday, reflecting steadier but less dramatic momentum. OMER’s volatility underscores its speculative nature, driven by a single-product milestone versus AMGN’s diversified pipeline. However, the FDA’s endorsement of Yartemlea could catalyze a broader biotech rally if TA-TMA adoption meets expectations, particularly given the 30,000 annual allogeneic transplants in the U.S. and Europe.

Options and ETF Plays for OMER’s Volatile Trajectory
• 200-day average: $5.80 (well below current price)
• RSI: 33.30 (oversold territory)
• MACD: 0.21 (bullish divergence)
• Bollinger Bands: $8.16–$11.75 (current price far above range)

OMER’s technicals suggest a continuation of its bullish breakout, with key resistance at $17.65 (52-week high) and support at $13.92 (intraday low). The RSI in oversold territory and MACD divergence hint at potential follow-through. For leveraged exposure, no ETF data is available, but options offer high-conviction plays. Two top options from the chain are:

• OMER20260116C15
- Type: Call
- Strike: $15
- Expiry: 2026-01-16
- IV: 133.52% (high volatility)
- LVR: 6.39% (moderate leverage)
- Delta: 0.6198 (moderate sensitivity)
- Theta: -0.055177 (rapid time decay)
- Gamma: 0.071023 (high sensitivity to price swings)
- Turnover: $1,180,595 (liquid)
- Payoff at 5% upside ($16.64): $1.64 per contract. This call offers a balance of leverage and liquidity, ideal for capitalizing on a sustained rally toward $17.65.

• OMER20260116C16
- Type: Call
- Strike: $16
- Expiry: 2026-01-16
- IV: 133.28% (high volatility)
- LVR: 7.83% (strong leverage)
- Delta: 0.5462 (moderate sensitivity)
- Theta: -0.055597 (rapid time decay)
- Gamma: 0.074041 (high sensitivity to price swings)
- Turnover: $1,207,413 (liquid)
- Payoff at 5% upside ($16.64): $0.64 per contract. This strike offers higher leverage but lower intrinsic value, suiting aggressive bulls targeting a breakout above $16.

Actionable Insight: Aggressive bulls may consider OMER20260116C15 into a test of $17.65, while conservative traders might use OMER20260116C16 for a leveraged play on a sustained rally. Both contracts benefit from high gamma and liquidity, making them ideal for a continuation of OMER’s momentum.

Backtest Omeros Stock Performance
The backtest of OMER's performance after an 81% intraday surge from 2022 to the present reveals mixed results. While the stock experienced a significant surge, the subsequent performance was volatile, with maximum returns of 21.60% over a 30-day period, but with a 30-day win rate of only 57.84%. This suggests that while OMER had a strong initial reaction to the surge, it struggled to maintain consistent gains in the following days.

OMER’s Breakout: A New Era for TA-TMA Treatment and Shareholder Value
OMER’s 81% surge on FDA approval of Yartemlea marks a pivotal moment for Omeros and the TA-TMA market. The stock’s technicals and options activity suggest a continuation of the rally, with $17.65 as the next key level. Investors should monitor the January 2026 U.S. launch and European regulatory progress, which could drive further gains. Meanwhile, Amgen (AMGN)’s 0.4% rise highlights the sector’s broader stability, offering a benchmark for OMER’s volatility. Act now: Position in OMER20260116C15 for a balanced play on the breakout or OMER20260116C16 for higher leverage. Watch for $17.65 clearance and EMA approval updates in mid-2026.